ArticleThoracic cancer2020

Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial.

Nobuaki Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.